OncoTelic Overview
- Year Founded
-
1988
- Status
-
Public
- Employees
-
13
- Stock Symbol
-
OTLC
- Investments
-
2
- Share Price
-
$0.01
- (As of Friday Closing)
OncoTelic General Information
Description
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. OT-101 is its flagship immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, AL-101, and Oxi4503.
Contact Information
Website
www.oncotelic.comCorporate Office
- 29397 Agoura Road
- Suite 107
- Agoura Hills, CA 91301
- United States
Corporate Office
- 29397 Agoura Road
- Suite 107
- Agoura Hills, CA 91301
- United States
OncoTelic Stock Performance
As of 20-Nov-2026, OncoTelic’s stock price is $0.01. Its current market cap is $5.9M with 458M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.01 | $0.01 | $0.01 - $0.10 | $5.9M | 458M | 389K | $0.58 |
OncoTelic Financials Summary
As of 30-Sep-2026, OncoTelic has a trailing 12-month revenue of $250K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 22,653 | 47,187 | 26,321 | 26,920 |
| Revenue | 250 | 0 | 0 | 70 |
| EBITDA | 359,928 | 361,460 | (3,922) | (7,161) |
| Net Income | 247,432 | 249,280 | (4,524) | (7,903) |
| Total Assets | 393,813 | 393,088 | 26,677 | 30,015 |
| Total Debt | 14,325 | 13,912 | 13,088 | 12,574 |
OncoTelic Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
OncoTelic Comparisons
Industry
Financing
Details
OncoTelic Competitors (4)
One of OncoTelic’s 4 competitors is Immune-Onc Therapeutics, a Venture Capital-Backed company based in Palo Alto, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Immune-Onc Therapeutics | Venture Capital-Backed | Palo Alto, CA | ||||
| Lyell Immunopharma | Formerly VC-backed | South San Francisco, CA | ||||
| Nkarta Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Pyxis Oncology | Formerly VC-backed | Boston, MA |
OncoTelic Patents
OncoTelic Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026207089-A1 | Methods and compositions for antisense cancer therapeutics | Pending | 26-Mar-2025 | ||
| WO-2025250885-A1 | In situ tumor-infiltrating lymphocyte therapeutics for cancer | Pending | 31-May-2024 | ||
| AU-2024388416-A1 | Structures and methods for autonomous agents | Pending | 29-Nov-2023 | ||
| EP-4816939-A1 | Structures and methods for autonomous agents | Pending | 29-Nov-2023 | ||
| US-20260329914-A1 | Structures and methods for autonomous agents | Pending | 29-Nov-2023 | G06F16/3347 |
OncoTelic Signals
OncoTelic Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
OncoTelic Investments & Acquisitions (2)
OncoTelic’s most recent deal was a Joint Venture with GMP Biotechnology. The deal was made on 31-Mar-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| GMP Biotechnology | 31-Mar-2022 | Joint Venture | Drug Discovery | ||
| Mateon Therapeutics | 25-Apr-2019 | Merger/Acquisition | Drug Discovery |
OncoTelic ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
OncoTelic Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| OncoTelic (Necroptosis Cancer Therapy Assets) | Agoura Hills, CA |
OncoTelic FAQs
-
When was OncoTelic founded?
OncoTelic was founded in 1988.
-
Where is OncoTelic headquartered?
OncoTelic is headquartered in Agoura Hills, CA.
-
What is the size of OncoTelic?
OncoTelic has 13 total employees.
-
What industry is OncoTelic in?
OncoTelic’s primary industry is Biotechnology.
-
Is OncoTelic a private or public company?
OncoTelic is a Public company.
-
What is OncoTelic’s stock symbol?
The ticker symbol for OncoTelic is OTLC.
-
What is the current stock price of OncoTelic?
As of 20-Nov-2026 the stock price of OncoTelic is $0.01.
-
What is the current market cap of OncoTelic?
The current market capitalization of OncoTelic is $5.9M.
-
What is OncoTelic’s current revenue?
The trailing twelve month revenue for OncoTelic is $250K.
-
Who are OncoTelic’s competitors?
Immune-Onc Therapeutics, Lyell Immunopharma, Nkarta Therapeutics, and Pyxis Oncology are competitors of OncoTelic.
-
What is OncoTelic’s annual earnings per share (EPS)?
OncoTelic’s EPS for 12 months was $0.58.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process